

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UMP HEALTHCARE HOLDINGS LIMITED

聯合醫務集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 722)

POSITIVE PROFIT ALERT

This announcement is made by UMP Healthcare Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the information currently available to the Board and the Board’s preliminary review on the unaudited consolidated management accounts of the Group for the year ended 30 June 2022 (the “**FY2022**”), the profit attributable to owners of the Company for the FY2022 is expected to increase by not less HK\$50 million or 150% as compared to the profit attributable to owners of the Company for the year ended 30 June 2021 (the “**FY2021**”), which is approximately HK\$34.8 million.

Such significant increase was primarily attributable to certain one-off items, namely (i) the gain on disposals of certain equity interests of investment in the discontinued operation (namely the corporate healthcare solutions business and provision of professional training business in Mainland China operated under UMP Healthcare China Limited, as a result of the reorganisation of the Group effective from 31 December 2021 as described in the Company’s announcement dated 22 December 2021) and the deemed disposal of certain interest in UMP Healthcare China Limited as a result of the subsequent equity dilution; (ii) a reversal of non-cash share warrant expenses; and (iii)

decrease in the impairment of goodwill, financial assets and other receivables. It is expected that, prior to the inclusion of the one-off items, the profit of the Company for the FY2022 shall achieve an overall increase as compared to the corresponding figure in FY2021, mainly attributable to the reduction of sharing of loss from the discontinued operation as a result of the reorganisation. The revenue and gross profit of the Company in FY2022 are also expected to represent a moderate increase as compared to the corresponding figures in FY 2021.

As at the date of this announcement, the Company is still in the process of finalising the Group's annual results for the year ended 30 June 2022. The information contained in this announcement only represents a preliminary assessment based on the information made available to the Board as at the date hereof and such information has not been reviewed or audited by the independent auditors of the Company or reviewed by the Audit Committee of the Company. The annual results of the Group for the year ended 30 June 2022 may be subject to further adjustment(s) and may be different from the information contained in this announcement. Further details of the Group's financial information will be published in the Company's announcement of annual results for the year ended 30 June 2022, which is expected to be published before the end of September 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board
UMP Healthcare Holdings Limited
SUN Yiu Kwong
Chairman and Chief Executive Officer

Hong Kong, 9 August 2022

As at the date of this announcement, the Executive Directors of the Company are Dr. SUN Yiu Kwong (Chairman and Chief Executive Officer), Ms. KWOK Cheuk Kwan, Jacquen (Managing Director), Mr. TSANG On Yip, Patrick, Dr. SUN Man Kin, Michael, Mr. LEE Kar Chung, Felix and Dr. LEE Pak Cheung, Patrick; and the Independent Non-executive Directors are Mr. LEE Luen Wai, John, Dr. LI Kwok Tung, Donald, Mr. YEUNG Wing Sun, Mike and Mr. CHAU, Chit Jeremy.